Articles from Bexorg, Inc.

NEW HAVEN, Conn., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Bexorg, Inc., a precision neurology company, built on an integrated AI and whole-human brain platform, today announced the appointment of Mikael Dolsten, M.D., Ph.D., as Chairman of its Board of Directors. Dr. Dolsten brings more than three decades of global leadership across research and development, including strategy and portfolio management, with experience spanning small-molecule medicines, biotherapeutics, gene therapies and vaccines. He succeeds Zvonimir Vrselja, M.D., Ph.D., Co-Founder and Chief Executive Officer, who has served as Chairman since the company’s founding and will continue as CEO and a member of the Board. The company also announced that Jon Faiz Kayyem, Ph.D., is retiring from the Board after serving as an independent director.

- Three-phase, 36-month award aims to extend BrainEx perfusion from 24 hours to up to two weeks, enabling longitudinal studies of human brain biology and therapeutic responses -

- Dr. Car brings more than 30 years of drug discovery experience to lead Bexorg's next phase of clinical translation; Dr. Fenn joins Bexorg to lead business development, asset strategy, and corporate development

- TRPML1 is a promising target1 for Parkinson’s disease treatments and identifying translational biomarkers will help confirm target engagement in clinical studies